Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-hydroxy beta-methylbutyric acid (HMB) is a naturally occurring small molecule produced in humans as a metabolite of the branched-chain amino acid L-leucine. It is found in small amounts in certain foods and is also produced endogenously in the liver and muscle cells. HMB has been widely studied for its potential to stimulate muscle protein synthesis, inhibit muscle protein breakdown, increase lean body mass, and support recovery after strenuous exercise or in situations of muscle wasting such as cancer, HIV/AIDS, or age-related sarcopenia. As a dietary supplement, HMB is used mainly by athletes and elderly individuals to help preserve muscle mass and strength. It is not associated with significant adverse effects when used as directed. Importantly, HMB is a metabolite and not a protein target, receptor, enzyme, or transporter[1][5][6][7].
HMB exerts effects by stimulating protein synthesis and inhibiting protein breakdown in muscle tissue
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-hydroxy beta-methylbutyric acid (HMB).